Galectin Therapeutics Inc. Common Stock (Galectin Therapeutics Inc. Common Stock (GALT) is lower by Thursday morning, with the stock declining -4.24% in pre-market trading to 2.26.
GALT's short-term technical score of 31 indicates that the stock has traded less bullishly over the last month than 69% of stocks on the market. In the Biotechnology industry, which ranks 141 out of 146 industries, Galectin Therapeutics Inc. Common Stock ranks higher than 55% of stocks.
Galectin Therapeutics Inc. Common Stock has fallen 5.60% over the past month, closing at $2.31 on March 18. During this period of time, the stock fell as low as $2.03 and as high as $3.27. GALT has an average analyst recommendation of Strong Buy. The company has an average price target of $12.00.
Galectin Therapeutics Inc. Common Stock has a Long-Term Technical rank of 23. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 77% of the market scoring higher. In the Biotechnology industry which is number 138 by this metric, GALT ranks better than 48% of stocks.
Important Dates for Investors in GALT:
-Galectin Therapeutics Inc. Common Stock is set to release earnings on 5/10/2021. During their last earnings release the company posted EPS of $-0.40. -We do not have a set dividend date for Galectin Therapeutics Inc. Common Stock at this time. Click Here to get the full Stock Score Report on Galectin Therapeutics Inc. Common Stock (GALT) Stock.
